
VP Hematology (TIME) @TempusAI #PrecisionMedicine #mmsm #lymsm #MDSsm #leusm #CCC19 @COVID19nCCC @ASCO COI: https://xitter.cf/t.co/A6GQmWYvau
Milwaukee, WI
Joined September 2010
- Tweets148K
- Following4K
- Followers23K
- Likes152K
Pinned Tweet
Whole-Genome Sequencing [WGS] of Pts w/ Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard-of-Care Methods [8/31/26] @AlexBataller et al. @garciamanero #SOHO2026 MDS-1210
clinical-lymphoma-myeloma-le… #MDSsm #leusm #cagenome @UTMDAnderson @TempusAI
Replying to @myESMO
@myESMO 2026: Day 3 Preview
Explore #ESMO26 insights here: clin.larvol.com/conference/a…
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #LungCancer #LCSM #SCLC #NSCLC #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @ADesaiMD | @lungoncdoc | @DrJNaidoo | @Erman_Akkus | @ilyassahinMD | @neerajaiims | @montypal
Mike Thompson, MD, PhD, FASCO retweeted
👉👉👉Thinking about future directions for research & education in #BPDCN for 2026 & beyond with the dynamic duo of @doctorpemm & @Daver_Leukemia after #FridayClinic #leusm #endcancer #Leadership #CD123456 | @homesforhealers @sanamloghavi
ascopubs.org/doi/10.1200/JCO…
Mike Thompson, MD, PhD, FASCO retweeted
👉👉👉Our group’s New paper 📑 just out in @Bloodneoplasia ➡️ led by Dr @niranjankhaire & Dr .@NitinJainMD ||
Combination therapy for adult patients with R/R T-ALL/LBL with Nelarbine + Pegaspargase + Venetoclax
sciencedirect.com/science/ar…
#leusm #endcancer
Mike Thompson, MD, PhD, FASCO retweeted
Replying to @dgkhalaf
Great question! In our cohort, we saw rapid evolution (< 6 mo) of PPM1D ± TP53-mutated clones following radioligand therapy, CAR-T, and PARPi-based therapy. The tempo and clinical trajectory, however, appeared to vary with the concurrent evolution/acquisition of additional somatic or chromosomal hits. Link to paper 📝 doi.org/10.1182/bloodadvance…
Mike Thompson, MD, PhD, FASCO retweeted
Excellent overview by @NivenMehra of emerging immune therapies in #ProstateCancer at #ESMO26!
• Promising early signals with KLK2×CD3 & masked PSMA×CD3 T-cell engagers
• Personalized neoantigen vaccines gaining traction
• CAR-T remains proof-of-concept
@myESMO @oncoalert
Sad that the @myESMO embargo was broken...
It is difficult to compare results between an adjuvant study and a neoadjuvant study (ie, S1801) in any cancer, including #melanoma. The patient populations were different and the primary endpoint (RFS vs EFS) was of necessity different for technical reasons that as @adamfeuerstein points out don't translate well to this platform. Until tomorrow's presentation we won't have all the data necessary to even try and compare.
It is also important to note that NO drugs are technically @FDA approved for neoadjuvant treatment for melanoma. It's a moot point as several studies including S1801 and NADINA have made neoadjuvant therapy standard of care in some situations.
I think it's great that the study (that I participated in) appears to have hit its primary endpoint, which typically ultimately translates into FDA approval.
Tomorrow (1030 ET) will be interesting...
Mike Thompson, MD, PhD, FASCO retweeted
Alzheimer’s is one of the most complex, heartbreaking challenges in modern healthcare. And if we’re ever going to make real progress against a disease this devastating, we need two things: unprecedented data scale and computing power.
When you bring together @bmsnews drug development expertise, @pathos agentic AI, and @TempusAI data infrastructure, you create something rare: a real opportunity to uncover novel insights, fix flawed trial designs, and actually accelerate precision treatments for patients who can't afford to wait.
Today we announced a strategic collaboration with @bmsnews to support their oncology drug portfolio.
We also announced a strategic collaboration with Bristol Myers Squibb and @pathos to advance drug discovery in Alzheimer’s disease.
Collectively, this makes BMS one of our largest data and modeling customers. Through this collaboration, BMS researchers will be able to train advanced AI models using de-identified data to surface breakthroughs and increase the probability of success when developing therapies for both cancer patients and those suffering from Alzheimer’s disease.
Read on: pathos.com/pathos-ai-announc… & tempus.com/news/pr/tempus-ex…
Mike Thompson, MD, PhD, FASCO retweeted
#Myeloma Paper of the Day: The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program marked by EOMES expression and motif accessibility, but not exhaustion profile supporting both persistence and effector function: pubmed.ncbi.nlm.nih.gov/4290…. #mmsm
Today we announced a strategic collaboration with @bmsnews to support their oncology drug portfolio.
We also announced a strategic collaboration with Bristol Myers Squibb and @pathos to advance drug discovery in Alzheimer’s disease.
Collectively, this makes BMS one of our largest data and modeling customers. Through this collaboration, BMS researchers will be able to train advanced AI models using de-identified data to surface breakthroughs and increase the probability of success when developing therapies for both cancer patients and those suffering from Alzheimer’s disease.
Read on: pathos.com/pathos-ai-announc… & tempus.com/news/pr/tempus-ex…
Mike Thompson, MD, PhD, FASCO retweeted
🇨🇳 TQB2102 (biparatopic HER2 TOPO1 ADC) also passes the truck test in mostly HR+/HER2-low MBC. PFS 16.4 vs 5.5 mo, HR 0.29, p<0.01. Unclear whether the biparatopic design adds anything. The HER2 TOPO1 field is getting quite crowded with excellent agents. #ESMOAmbassadors #ESMO26
Mike Thompson, MD, PhD, FASCO retweeted
1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO
5 of these phase 3s already announced positive toplines. ESMO is where we finally see effect sizes.
The question each one answers 🧵 #LCSM
@LungCancerRx @OncoAlert @oncodaily
Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26
statnews.com/2026/10/23/esmo…
Reduced toxicity data is particularly important as a lower Daraxonrasib dose can be used.
Mike Thompson, MD, PhD, FASCO retweeted
Excellent presentation by Jens presenting results from KN866 trial that did not meet its primary endpoint in contrast with NIAGARA. Peri-op EV-pembro is the SOC in MIBC, awaiting VOLGA trial tomorrow! @myESMO #ESMO26 #ESMOAmbassadors @OncoAlert @Uromigos @shilpaonc @AndreaNecchi
Replying to @myESMO
@myESMO 2026: Day 1 Preview
Explore #ESMO26 insights here: clin.larvol.com/conference/a…
#LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BreastCancer #TNBC #BCSM #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @PTarantinoMD | @ErikaHamilton9 | @stolaney1 | @pashtoonkasi | @ArndtVogel | @Erman_Akkus | @DrChoueiri | @DrYukselUrun | @neerajaiims
Mike Thompson, MD, PhD, FASCO retweeted
Do you have newly diagnosed #MultipleMyeloma and are either ineligible for or willing to delay #StemCell transplantation? If so, you may be eligible to participate in #ClinicalTrial EAA181/EQUATE. More info here: bit.ly/eaa181equate #MMSM #NDMM cc: @MM_Hub, @theMMRF
Mike Thompson, MD, PhD, FASCO retweeted
Beyond excited to recruit @VivekSubbiah to @nyulangone @Perlmutter_CC as the new director of our Early Phase Drug Development Program and the Rare Cancer Program.
Congratulate Vivek when you see him at #ESMO26. Welcome to NYC!
@JohnPLeonardMD
nyulangone.org/news/perlmutt…
Tempus delivers insight generation at scale.
Our comprehensive, AI-powered platform supports every stage of drug development—from discovery through commercialization.
Heading to #ESMO26? Visit Booths #1068 & #1069 to connect with our team and explore our latest innovations.
Learn more: tempus.co/4jFLmh3
When the immune system is weakened by cancer treatment — especially by a stem cell or bone marrow transplant (BMT) for blood cancer — common viruses like herpes simplex virus (HSV) can become a serious problem.
For someone who is immunocompromised, an HSV infection can mean dealing with large, painful sores that resist the usual therapies and ultimately lead to more critical medical conditions.
The good news: The @FDA recently approved #pritelivir (Hovilpri) for HSV infection in immunocompromised patients, including those who are undergoing cancer treatment.
The study that resulted in the drug’s approval was co-led by Dr. @GenPapaMD, Clinical Director for Infectious Diseases at MSK, and Dr. June Lee, an infectious disease specialist at MSK, among others.
Learn more: bit.ly/4eLLnMO
Mike Thompson, MD, PhD, FASCO retweeted
I really admire figures that can describe a concept better than long manuscripts.
This image is from an excellent paper in Nature by Vivek Subbiah about the future of evidence-based medicine and the design of clinical trials, all inspired by the rise of artificial intelligence.
This is the era of the next generation of 'deep' medicine.
"Current paradigms must be continuously challenged by emerging technology and by all stakeholders (the new generations of scientists, physicians, the pharma industry, regulatory authorities and, most importantly, patients). Disruptive innovation should lead to every clinical site being a research site, with all necessary quality checks and research as part of the standard of care.
My personal view is that every major disease needs a ‘Moonshot’ program and every rare disease should have an ‘Operation Warp Speed’—both with clearly identified, sustainable goals to improve population health and address equity, diversity and global access to therapies.
Methodological advances and future AI-based analyses of all data will provide deep evidence to realize the goal of personalized medicine— that is, to offer the right treatment to the right patient at the right time."
The paper: nature.com/articles/s41591-0…
















































